Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Development

Arvinas partners with Novartis for prostate cancer drugs

by Sarah Braner
April 18, 2024 | A version of this story appeared in Volume 102, Issue 12

 

Novartis has agreed to license Arvinas’s protein-degradation prostate cancer drug ARV-766. This clinical-stage candidate targets mutated androgen receptors that are thought to confer resistance to cancer drugs. Arvinas has also sold to Novartis its preclinical program that targets AR-V7, a variant androgen receptor that may also allow cancer cells to evade existing treatments. Arvinas will receive an up-front payment of $150 million, with the potential for $1 billion in milestone and royalty payments.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.